ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

September 30, 2017

Conditions
Breast CancerBrain Metastases
Interventions
DRUG

ANG1005

Trial Locations (19)

11725

The Long Islan Brain Tumor Center at Neurological Surgery P.C., Commack

15213

Magee Womens Hospital, Pittsburgh

15232

UPMC Cancer Center, Pittsburgh

21201

University of Maryland - Greenebaum Cancer Center, Baltimore

30912

GRU Cancer Center - Georgia Regents University, Augusta

44195

Cleveland Clinic, Cleveland

49503

Cancer & Hematology Centers of Western Michigan, Grand Rapids

60611

Northwestern University, Chicago

77030

MD Anderson Cancer Center, Houston

78229

Univeristy of Texas Health Science Center in San Antonio, San Antonio

80045

University of Colorado Cancer Center, Aurora

85719

University of Arizona Cancer Center, Tucson

87106

University of New Mexico, Albuquerque

90033

University of California - LAC Medical Center, Los Angeles

University of Southern California - Norris Comprehensive Cancer Center, Los Angeles

92868

UC - Irvine Chao Family Comprehensive Cancer Center, Orange

92093-0698

UC San Diego Moores Cancer Center, La Jolla

20892-1903

National Cancer Institute, Bethesda

27599-7295

University of North Carolina at Chapel Hill, Chapel Hill

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Angiochem Inc

INDUSTRY

NCT02048059 - ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases | Biotech Hunter | Biotech Hunter